V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

LivaNova PLC Executive Compensation (FY25)

LIVN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Vladimir Makatsaria
Latest say-on-pay support
=
June 10, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on LivaNova PLC

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 11, 2026
6 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
LivaNova PLC brief$1,500Get the executive brief
Velarion Member, one year
335 figures on this page: 333 cited to the filing that reported them, 2 calculated from figures it prints. See the citations

More on LivaNova PLC

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Vladimir Makatsaria: $9,710,672 → $8,047,217 (17.1% lower)
CEO pay ratio: 135:1 → 101:1 (25.2% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is LivaNova PLC's chief executive and what were they paid?
Vladimir Makatsaria, Chief Executive Officer, received $8,047,217 in total compensation for fiscal 2025. Makatsaria's total was 17.1% lower than the $9,710,672 reported for fiscal 2024.
What was LivaNova PLC's say-on-pay result?
Shareholders recorded 99.0% support for the say-on-pay proposal at the meeting held June 10, 2026 for fiscal 2025.
Which companies are in LivaNova PLC's peer group?
The disclosed peer group names Avanos Medical, Inc., CONMED Corporation, Enovis Corporation, Globus Medical, Inc. and Haemonetics Corporation, among others.
What is LivaNova PLC's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 101:1, against median employee compensation of $79,459.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Damien McDonald
Former CEO
Departed during or after this year
◇—◇◇◇—◇◇
Keyna Skeffington
and Former SVP and General Counsel
Departed during or after this year
◇—◇◇◇—◇◇
Marco Dolci
President, Cardiopulmonary BU
◇—◇◇◇—◇◇
Alex Shvartsburg
CFO
◇—◇◇◇—◇◇
Trui Hebbelinck
CHRO
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Alex Shvartsburg
CFO
◇—◇◇◇—◇◇
Michael Hutchinson
Former Chief Legal Officer
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vladimir Makatsaria
Chief Executive Officer
◇◇◇◇◇—◇◇
Alex Shvartsburg
Chief Financial Officer
◇—◇◇◇—◇◇
Ahmet Tezel
Chief Innovation Officer
◇—◇◇◇—◇◇
Trui Hebbelinck
Former CHRO
Departed during or after this year
◇—◇◇◇—◇◇
Michael Hutchinson
Chief Legal Officer
◇—◇◇◇—◇◇
Franco Poletti
President, Cardiopulmonary Business Unit
◇—◇◇◇—◇◇
William Kozy
Former Interim CEO
Departed during or after this year
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Vladimir Makatsaria
Chief Executive Officer
◇—◇◇◇—◇◇
Alex Shvartsburg
Chief Financial Officer
◇—◇◇◇—◇◇
Ahmet Tezel
Senior Vice President, Chief Innovation Officer
◇—◇◇◇—◇◇
Natalia Kozmina
Chief Human Resources Officer
◇◇◇◇◇—◇◇
Michael Hutchinson
Former Senior Vice President, Chief Legal Officer and Company Secretary
Departed during or after this year
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Ahmet TezelPSU◇—◇—◇—◇
Ahmet TezelPSU◇—◇—◇—◇
Ahmet TezelPSU◇—◇—◇—◇
Ahmet TezelRSU◇——◇——◇
Ahmet TezelOPTION◇——◇—◇◇
Alex ShvartsburgPSU◇—◇—◇—◇
Alex ShvartsburgRSU◇——◇——◇
Alex ShvartsburgPSU◇—◇—◇—◇
Alex ShvartsburgPSU◇—◇—◇—◇
Alex ShvartsburgOPTION◇——◇—◇◇
Natalia KozminaPSU◇—◇—◇—◇
Natalia KozminaRSU◇——◇——◇
Vladimir MakatsariaPSU◇—◇—◇—◇
Vladimir MakatsariaOPTION◇——◇—◇◇
Vladimir MakatsariaPSU◇—◇—◇—◇
Vladimir MakatsariaPSU◇—◇—◇—◇
Vladimir MakatsariaRSU◇——◇——◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Michael HutchinsonRSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Vladimir MakatsariaPSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Ahmet TezelRSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Natalia KozminaRSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
Alex ShvartsburgRSU◇◇——
PSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Alex Shvartsburg
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Kozy
Board chair
◇◇————◇
Todd Schermerhorn
◇◇————◇
J. Christopher Barry
◇◇————◇
Francesco Bianchi
◇◇————◇
Peter Wilver
◇◇————◇
Stacy Enxing Seng
◇◇————◇
Sharon O'Kane
◇◇————◇
Susan Podlogar
◇◇————◇
Brooke Story
◇◇————◇
Donald Zurbay
◇◇————◇
Jette Nygaard-Andersen and Vladimir Makatsaria served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Stock.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Avanos Medical, Inc. AVNS
  • CONMED Corporation CNMD
  • Enovis Corporation ENOV
  • Globus Medical, Inc. GMED
  • Haemonetics Corporation HAE
  • ICU Medical, Inc. ICUI
  • Inari Medical, Inc.(1) NARI
  • Inspire Medical Systems, Inc. INSP
  • Integer Holdings Corporation ITGR
  • Integra LifeSciences Holdings Corporation IART
  • Masimo Corporation MASI
  • Merit Medical Systems, Inc. MMSI
  • Nevro Corp.(2) NVRO
  • Penumbra, Inc.(3) PEN
  • Tandem Diabetes Care, Inc. TNDM

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 10, 2026=◇◇◇
2024June 11, 2025=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Vladimir Makatsaria (Chief Executive Officer), FY2025 total compensation $8,047,217 (base salary $956,115) [exec_comp, SEC accession 0001104659-26-050937, filed 2026-04-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when LivaNova PLC files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact LivaNova PLC disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where LivaNova PLC sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether LivaNova PLC's disclosed peer group is defensible, who names LivaNova PLC back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
335 figures on this page: 333 cited to the filing that reported them, 2 calculated from figures it prints.
333 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001639691-26-000053
  2. 0001104659-26-050937
    CEO Pay Ratio · COMPENSATION TABLES · Compensation Discussion and Analysis · Compensation Tables · and 1 more section
  3. 0001639691-25-000052
  4. 0001104659-25-041852
    Compensation Tables
  5. 0001104659-24-052902
    Summary Compensation Table
  6. 0001104659-23-052988
    Compensation Tables
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “LivaNova PLC executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/LIVN (accessed 2026).
Short form: data: Velarion

The paid brief for LivaNova PLC

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about LivaNova PLC and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers LivaNova PLC discloses

The companies named in LIVN's own disclosed peer group.

Avanos Medical, Inc.CONMED CorporationEnovis CorporationGlobus Medical, Inc.Haemonetics CorporationICU Medical, Inc.Inari Medical, Inc.(1)Inspire Medical Systems, Inc.Integer Holdings CorporationIntegra LifeSciences Holdings CorporationMasimo CorporationMerit Medical Systems, Inc.Nevro Corp.(2)Penumbra, Inc.(3)Tandem Diabetes Care, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy